Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
VERV - Verve Therapeutics, Inc.
Market Cap 1.18B P/E - EPS this Y 16.00% Ern Qtrly Grth -
Income -192.65M Forward P/E -4.99 EPS next Y -12.60% 50D Avg Chg 3.00%
Sales 20.65M PEG - EPS past 5Y - 200D Avg Chg -6.00%
Dividend N/A Price/Book 2.32 EPS next 5Y - 52W High Chg -56.00%
Recommedations 1.80 Quick Ratio 14.34 Shares Outstanding 84.62M 52W Low Chg 47.00%
Insider Own 1.78% ROA -21.51% Shares Float 62.40M Beta 1.84
Inst Own 91.56% ROE -38.10% Shares Shorted/Prior 15.87M/16.25M Price 19.12
Gross Margin - Profit Margin - Avg. Volume 604,911 Target Price 25.13
Oper. Margin -879.24% Earnings Date - Volume 479,433 Change -1.54%
Healthcare | Biotechnology | United States
About Verve Therapeutics, Inc.

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Verve Therapeutics, Inc. News
12/17/24 Verve Therapeutics Slides As Insider Purchases Lose Another US$65k
11/29/24 Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
11/06/24 Verve Therapeutics Third Quarter 2024 Earnings: Beats Expectations
11/05/24 Verve Therapeutics (VERV) Reports Q3 Loss, Tops Revenue Estimates
11/05/24 Verve Therapeutics: Q3 Earnings Snapshot
11/05/24 Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results
10/16/24 State Street Corp's Strategic Acquisition in Verve Therapeutics
10/03/24 Is Verve Therapeutics, Inc. (VERV) the Best NASDAQ Stock Under $5?
09/20/24 Jim Cramer on Vertiv Holdings (VRT): ‘I Think It’s A Winner’
09/12/24 Millennium Management LLC's Strategic Acquisition in Verve Therapeutics Inc
09/08/24 Verve Therapeutics, Inc. (VERV): Among the Worst ARK Stocks According to Short Sellers
08/08/24 Verve Therapeutics (VERV) Reports Q2 Loss, Lags Revenue Estimates
08/08/24 Verve Therapeutics: Q2 Earnings Snapshot
08/08/24 Verve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial Results
08/01/24 We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate
07/08/24 Why Is Verve Therapeutics, Inc. (VERV) the Most Shorted Stock Loved by Analysts Now?
06/28/24 Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
06/21/24 One Verve Therapeutics Insider Raised Stake By 29% In Previous Year
05/31/24 Verve Therapeutics Announces Leadership Update
05/30/24 Verve Therapeutics to Participate in Upcoming Investor Conferences
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Bellinger Andrew CSO & CMO CSO & CMO Dec 14 Option 2.87 36,000 103,320 42,629 12/16/22
Bellinger Andrew CSO & CMO CSO & CMO Dec 01 Sell 22.95 865 19,852 6,629 12/02/22
Yeshwant Krishna Director Director Nov 04 Sell 32 48,583 1,554,656 4,260,047 11/08/22
GV 2017 GP, L.L.C. Other Other Nov 04 Sell 32 97,166 3,109,312 4,260,047 11/08/22
GV 2017 GP, L.L.C. Other Other Nov 02 Sell 34.52 156,440 5,400,309 4,308,630 11/04/22
Yeshwant Krishna Director Director Oct 31 Sell 38.69 85,659 3,314,147 4,386,850 11/02/22
Ashe Andrew D. See Remarks See Remarks Aug 25 Option 1.91 95,787 182,953 266,509 08/29/22
Kathiresan Sekar Chief Executive Offi.. Chief Executive Officer Aug 10 Option 1.39 50,000 69,500 367,839 08/11/22
Kathiresan Sekar Chief Executive Offi.. Chief Executive Officer Aug 10 Sell 29.9 50,000 1,495,000 317,839 08/11/22
Bellinger Andrew CSO & CMO CSO & CMO Jul 20 Option 1.39 20,000 27,800 26,629 07/22/22
Bellinger Andrew CSO & CMO CSO & CMO Jul 20 Sell 34.9 20,000 698,000 6,629 07/22/22
Kathiresan Sekar Chief Executive Offi.. Chief Executive Officer Jul 19 Option 1.39 50,000 69,500 367,839 07/21/22
Kathiresan Sekar Chief Executive Offi.. Chief Executive Officer Jul 19 Sell 29.9 50,000 1,495,000 317,839 07/21/22
Bellinger Andrew CSO & CMO CSO & CMO Jul 13 Option 1.48 10,000 14,800 16,629 07/15/22
Bellinger Andrew CSO & CMO CSO & CMO Jul 13 Sell 24.9 10,000 249,000 6,629 07/15/22
FMR LLC 10% Owner 10% Owner Jul 12 Sell 21.01 163,000 3,424,630 570,729 07/14/22
Kathiresan Sekar Chief Executive Offi.. Chief Executive Officer Mar 18 Option 2.87 69,674 199,964 477,525 03/22/22
ADELMAN BURT A Director Director Mar 15 Buy 21.3838 4,000 85,535 8,700 03/17/22
FMR LLC 10% Owner 10% Owner Mar 09 Sell 29.01 3,971 115,199 825,723 03/11/22
FMR LLC 10% Owner 10% Owner Feb 09 Sell 29.46 13,190 388,577 829,694 02/11/22
FMR LLC 10% Owner 10% Owner Feb 01 Sell 29.04 35,574 1,033,069 842,884 02/03/22
FMR LLC 10% Owner 10% Owner Jan 26 Sell 30.41 158,836 4,830,203 878,458 01/28/22
Bellinger Andrew Chief Scientific Off.. Chief Scientific Officer Dec 22 Option 1.48 15,000 22,200 20,000 12/27/21
Bellinger Andrew Chief Scientific Off.. Chief Scientific Officer Dec 22 Sell 38.47 15,000 577,050 5,000 12/27/21
Kathiresan Sekar Chief Executive Offi.. Chief Executive Officer Dec 22 Option 1.39 114,000 158,460 463,536 12/27/21
Kathiresan Sekar Chief Executive Offi.. Chief Executive Officer Dec 22 Sell 38.89 114,000 4,433,460 406,536 12/27/21